statistiche ricercatore

Continente	#
NA - Nord America	467
AS - Asia	325
EU - Europa	244
SA - Sud America	30
AF - Africa	20
Continente sconosciuto - Info sul continente non disponibili	17
OC - Oceania	3
Totale	1.106

Nazione	#
US - Stati Uniti d'America	450
CN - Cina	158
IE - Irlanda	77
SG - Singapore	69
RU - Federazione Russa	37
VN - Vietnam	37
HK - Hong Kong	33
IT - Italia	27
BR - Brasile	20
FI - Finlandia	20
DE - Germania	19
FR - Francia	17
GB - Regno Unito	11
CA - Canada	7
EG - Egitto	7
IN - India	7
MX - Messico	7
ZA - Sudafrica	6
ES - Italia	4
JP - Giappone	4
SE - Svezia	4
TR - Turchia	4
BE - Belgio	3
CL - Cile	3
IS - Islanda	3
NL - Olanda	3
UA - Ucraina	3
AR - Argentina	2
AT - Austria	2
BD - Bangladesh	2
CO - Colombia	2
HU - Ungheria	2
ID - Indonesia	2
IQ - Iraq	2
KR - Corea	2
NO - Norvegia	2
NZ - Nuova Zelanda	2
PL - Polonia	2
AL - Albania	1
AU - Australia	1
BA - Bosnia-Erzegovina	1
BO - Bolivia	1
DK - Danimarca	1
DZ - Algeria	1
EC - Ecuador	1
ET - Etiopia	1
GR - Grecia	1
HN - Honduras	1
IR - Iran	1
KE - Kenya	1
KW - Kuwait	1
KZ - Kazakistan	1
LT - Lituania	1
LV - Lettonia	1
MA - Marocco	1
MY - Malesia	1
NG - Nigeria	1
PK - Pakistan	1
RO - Romania	1
SK - Slovacchia (Repubblica Slovacca)	1
SV - El Salvador	1
TN - Tunisia	1
TT - Trinidad e Tobago	1
VE - Venezuela	1
ZW - Zimbabwe	1
Totale	1.089

Nome	#
Methodological and practical issues in TMDD modeling with application to oncology	156
Methods and tools for multiscale modelling in Systems Pharmacology: a review	135
Evaluation of software tools for Bayesian estimation on population models with count and continuous data	118
Evaluation of software tools for Bayesian estimation on population models:an update based on current software versions	118
MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues	113
Current mathematical models for cancer drug discovery	109
Mathematical modeling of efficacy and safety for anticancer drugs clinical development	98
Assessing drug effect from distributional data: A population approach with application to Duchenne Muscular Dystrophy treatment	93
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial	86
Pharmacokinetic Models for Drug and Metabolites Including First Pass Effects: A Priori and A Posteriori Identifiability Analysis	80
Totale	1.106

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	44	0	0	4	0	0	1	0	2	0	1	9	27
2022/2023	170	20	20	5	10	13	9	0	5	82	2	4	0
2023/2024	72	14	10	0	2	2	10	8	15	2	2	4	3
2024/2025	178	7	13	4	2	7	10	3	15	53	5	19	40
2025/2026	453	44	36	23	36	72	20	75	17	38	48	19	25
2026/2027	21	5	16	0	0	0	0	0	0	0	0	0	0
Totale													1.106